Study of the relationship between antiemetic effect of Aprepitant and plasma concentration of Aprepitant

Study of the relationship between antiemetic effect of Aprepitant and plasma concentration of Aprepitant - Study of the relationship between antiemetic effect of Aprepitant and plasma concentration of Aprepitant

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007048

Enrollment

Registered

2012-01-11

Start date

2012-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant tumor(esophageal cancer,gastric cancer etc.)

Interventions

Palonosetron:day1(0.75mg) Aprepitant:day1(125mg),2(80mg),3(80mg) Dexamethasone:day1(9.9mg) Dexamethasone:day2-4(8mg)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients who receive the chemotherapy involving cisplatin(>=50mg/m2) 2)20 years-old over at the time of giving informed consent 3)Informed consent by the document

Exclusion criteria

Exclusion criteria: 1)Receiving an antiemetic drug 2)Receiving an opioid 3)Any patients judged by the investigator to be unfit to participate in the study

Design outcomes

Primary

Measure	Time frame
Complete response rate in overall phase (0-120 hours after chemotherapy)	—

Countries

Japan

Contacts

Public ContactKosuke Nishizawa

Toho University School of Pharmaceutical Sciences Department of Clinical Pharmaceutics

k-nishizawa@med.toho-u.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026